Salaverria Itziar, Zettl Andreas, Beà Sílvia, Moreno Victor, Valls Joan, Hartmann Elena, Ott German, Wright George, Lopez-Guillermo Armando, Chan Wing C, Weisenburger Dennis D, Gascoyne Randy D, Grogan Thomas M, Delabie Jan, Jaffe Elaine S, Montserrat Emili, Muller-Hermelink Hans-Konrad, Staudt Louis M, Rosenwald Andreas, Campo Elias
Department of Pathology and Hematology, Hospital Clinic, University of Barcelona, Barcelona, Spain.
J Clin Oncol. 2007 Apr 1;25(10):1216-22. doi: 10.1200/JCO.2006.08.4251. Epub 2007 Feb 12.
To compare the genetic relationship between cyclin D1-positive and cyclin D1-negative mantle cell lymphomas (MCLs) and to determine whether specific genetic alterations may add prognostic information to survival prediction based on the proliferation signature of MCLs.
Seventy-one cyclin D1-positive and six cyclin D1-negative MCLs previously characterized by gene expression profiling were examined by comparative genomic hybridization (CGH).
Cyclin D1-negative MCLs were genetically characterized by gains of 3q, 8q, and 15q, and losses of 1p, 8p23-pter, 9p21-pter, 11q21-q23, and 13q that were also the most common alterations in conventional MCLs. Parallel analysis of CGH aberrations and locus-specific gene expression profiles in cyclin D1-positive patients showed that chromosomal imbalances had a substantial impact on the expression levels of the genes located in the altered regions. The analysis of prognostic factors revealed that the proliferation signature, the number of chromosomal aberrations, gains of 3q, and losses of 8p, 9p, and 9q predicted survival of MCL patients. A multivariate analysis showed that the gene expression-based proliferation signature was the strongest predictor for shorter survival. However, 3q gains and 9q losses provided prognostic information that was independent of the proliferative activity.
Cyclin D1-positive and -negative MCLs share the same secondary genetic aberrations, supporting the concept that they correspond to the same genetic entity. The integration of genetic information on chromosome 3q and 9q alterations into a proliferation signature-based model may improve the ability to predict survival in patients with MCL.
比较细胞周期蛋白D1阳性与阴性套细胞淋巴瘤(MCL)之间的遗传关系,并确定特定的基因改变是否可以为基于MCL增殖特征的生存预测增加预后信息。
对71例先前通过基因表达谱分析鉴定的细胞周期蛋白D1阳性MCL和6例细胞周期蛋白D1阴性MCL进行比较基因组杂交(CGH)检测。
细胞周期蛋白D1阴性MCL的遗传学特征为3q、8q和15q增益,以及1p、8p23 - pter、9p21 - pter、11q21 - q23和13q缺失,这些也是传统MCL中最常见的改变。对细胞周期蛋白D1阳性患者的CGH畸变和基因座特异性基因表达谱进行平行分析表明,染色体失衡对位于改变区域的基因表达水平有重大影响。预后因素分析显示,增殖特征、染色体畸变数量、3q增益以及8p、9p和9q缺失可预测MCL患者的生存情况。多变量分析表明,基于基因表达的增殖特征是较短生存期的最强预测指标。然而,3q增益和9q缺失提供了独立于增殖活性的预后信息。
细胞周期蛋白D1阳性和阴性MCL具有相同的继发性基因畸变,支持它们对应于同一遗传实体的概念。将3号染色体q臂和9号染色体q臂改变的遗传信息整合到基于增殖特征的模型中,可能会提高预测MCL患者生存的能力。